Avalyn Pharma Inc.
AVLN
$30.71
$1.735.97%
NASDAQ
| 03/31/2026 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.02M | 3.40M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.91M | 18.72M | |||
| Operating Income | -27.91M | -18.72M | |||
| Income Before Tax | -26.87M | -17.50M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.87M | -17.50M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.87M | -17.50M | |||
| EBIT | -27.91M | -18.72M | |||
| EBITDA | -27.85M | -18.71M | |||
| EPS Basic | -21.83 | -63.24 | |||
| Normalized Basic EPS | -13.65 | -39.52 | |||
| EPS Diluted | -21.83 | -63.24 | |||
| Normalized Diluted EPS | -13.65 | -39.52 | |||
| Average Basic Shares Outstanding | 1.23M | 276.80K | |||
| Average Diluted Shares Outstanding | 1.23M | 276.80K | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||